Biovie Inc. financial data

Symbol
BIVI on Nasdaq
Industry
Pharmaceutical Preparations
Location
680 W Nye Lane, Suite 201, Carson City, NV
State of incorporation
NV
Fiscal year end
June 30
Former names
NANOANTIBIOTICS, INC. (to 7/22/2016)
Latest financial report
10-K - Q2 2024 - Sep 30, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 200 % -41.9%
Debt-to-equity 107 % -9.32%
Return On Assets -126 % +6.01%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.96M shares -78.9%
Common Stock, Shares, Outstanding 6.19M shares +69.9%
Entity Public Float 20.6M USD
Common Stock, Value, Issued 6.23K USD +71%
Weighted Average Number of Shares Outstanding, Basic 4.52M shares +39.1%
Weighted Average Number of Shares Outstanding, Diluted 4.52M shares +39.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 23.1M USD -30.6%
Operating Income (Loss) -32.2M USD +28.6%
Nonoperating Income (Expense) -336K USD +73.5%
Net Income (Loss) Attributable to Parent -32.1M USD +36.1%
Earnings Per Share, Basic -7.3 USD/shares +52.8%
Earnings Per Share, Diluted -7.3 USD/shares +52.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 23.8M USD +22.5%
Other Assets, Current 285K USD +565%
Assets, Current 24M USD -29.4%
Operating Lease, Right-of-Use Asset 407K USD +403%
Intangible Assets, Net (Excluding Goodwill) 408K USD -36%
Goodwill 346K USD 0%
Other Assets, Noncurrent 4.56K USD
Assets 25.2M USD -28.2%
Accounts Payable, Current 3.59M USD +3.18%
Liabilities, Current 9.35M USD -35.5%
Operating Lease, Liability, Noncurrent 350K USD +723%
Other Liabilities, Noncurrent 48.4K USD
Liabilities 9.7M USD -50.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 177K USD
Retained Earnings (Accumulated Deficit) -334M USD -11%
Stockholders' Equity Attributable to Parent 15.5M USD +1.08%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 26.1M USD +62.3%
Liabilities and Equity 25.2M USD -28.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.2M USD -32.1%
Net Cash Provided by (Used in) Financing Activities -594K USD -105%
Net Cash Provided by (Used in) Investing Activities 14.5M USD
Common Stock, Shares Authorized 800M shares 0%
Common Stock, Shares, Issued 1.36M shares -96.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 23.8M USD +22.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 529K USD +12.5%
Deferred Tax Assets, Valuation Allowance 69.6M USD +14.9%
Operating Lease, Liability 410K USD +369%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -33.2M USD +33.7%
Lessee, Operating Lease, Liability, to be Paid 575K USD +494%
Operating Lease, Liability, Current 60.3K USD +34.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 118K USD +126%
Lessee, Operating Lease, Liability, to be Paid, Year One 29.1K USD +125%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure +37.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 165K USD +1655%
Lessee, Operating Lease, Liability, to be Paid, Year Three 122K USD +173%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 126K USD
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 229K USD 0%
Depreciation, Depletion and Amortization 57.3K USD 0%
Interest Expense 2.89M USD -32.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%